Inagaki, Koji
Kaihan, Ahmad Baseer
Hachiya, Asaka
Ozeki, Takaya
Ando, Masahiko
Kato, Sawako
Yasuda, Yoshinari
Maruyama, Shoichi http://orcid.org/0000-0002-8858-632X
Funding for this research was provided by:
Grant-in-Aid for Intractable Renal Diseases Research, Research on rare and intractable diseases, Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan (H29-Nanchitou(Nan)-Ippan-017)
Alexion Pharmaceuticals (US)
Asahi Kasei Pharma Corporation
Astellas Pharma
Baxter International
Bristol-Myers Squibb
Chugai Pharmaceutical
Daiichi-Sankyo
Kyowa Hakko Kirin
Merck Sharp and Dohme
Mitsubishi Tanabe pharma
Mochida Pharmaceutical Company
Novartis Pharmaceuticals Corporation
Otsuka Pharmaceutical
Pfizer Japan
Sanwa Kagaku Kenkyusho
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company
Teijin Pharma
Torii Pharmaceutical
Article History
Received: 31 March 2018
Accepted: 9 August 2018
First Online: 17 August 2018
Ethics approval and consent to participate
: This study was conducted in accordance with the principles of Declaration of Helsinki and was approved by the Ethics Committees of Nagoya University Hospital and other thirteen hospitals (approval number: 1135). All participants were informed that their medical records and renal biopsy specimens would be used for the research and signed an informed consent form at the time of kidney biopsy.
: Not applicable.
: Shoichi Maruyama (Alexion Pharmaceutical Inc., Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Baxter international Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Kyowa Hakko Kirin Co., Ltd., Merck Sharp and Dohme Inc., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanwa Kagaku Kenkyusho Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Ltd., Teijin Pharma Limited., and Torii Pharmaceutical Co., Ltd.). All other authors have declared no conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.